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A B S T R A C T
Objectives: Rotavirus is the major cause of severe diarrhea in young children worldwide. In countries like
Croatia, where rotavirus vaccine has not been introduced in the national immunization program,
prospective surveillance is necessary to establish the diversity of rotavirus strains. The aim of this study
was to describe the prevalence and geographical distribution of rotavirus strains in Croatia and to detect
the possible emergence of novel strains.
Methods: The study was conducted among children 5 years of age with acute gastroenteritis at three
hospitals located in different geographical regions of Croatia, during the years 2012 to 2014. Rotavirus
was detected in stools using an immunochromatographic assay and then sent for further molecular
analysis.
Results: Genotyping of 822 rotaviruses showed that the predominant circulating strain was G1P[8]
(61.9%), followed by G2P[4] (19.5%), G1P[4] (3.9%), and G3P[8] (2.9%). A high prevalence of reassortants
among common human rotavirus genotypes was detected (7.7%). Possible zoonotic reassortants were
found, including G8 and G6 strains. The latter is described for the first time in Croatia.
Conclusions: This study represents pre-vaccination data that are important for decisions regarding
immunization strategies in Croatia. The high prevalence of ‘common’ rotavirus strains circulating in
Croatia may advocate for rotavirus vaccine introduction, but further surveillance is necessary to monitor
the possible emergence of novel genotypes.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Diarrhea is one of the leading causes of mortality among young
children and is responsible for almost 500 000 deaths annually
worldwide (Wang et al., 2016; Troeger et al., 2017). Despite the
decreasing number of cases, rotavirus (RV) is still the main global
cause of diarrhea-associated morbidity and mortality in children* Corresponding author.
E-mail address: mvrdoljak@bfm.hr (M. Vrdoljak).
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1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).younger than 5 years of age; it is considered responsible for nearly
260 million diarrhea episodes and one-third of all diarrhea-related
deaths in 2016 (Troeger et al., 2018). In developed countries, the
mortality rates associated with RV are significantly lower than
those in developing countries (Tate et al., 2016; Troeger et al.,
2018), but RV infection is still responsible for considerable
morbidity and health costs (Rheingans et al., 2006; Troeger
et al., 2018).
Group A RVs are classified into G and P types based on the
sequence diversity of the genes encoding the outer viral proteins
VP7 (glycoprotein) and VP4 (protease-sensitive protein)iety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
4 M. Vrdoljak et al. / International Journal of Infectious Diseases 89 (2019) 3–9(Matthijnssens et al., 2008). Comprehensive reviews of G and P
type prevalence data before the introduction of RV vaccines have
indicated the global importance of five genotypes: G1P[8], G2P[4],
G3P[8], G4P[8], and G9P[8]; however, a great diversity of G/P
combinations has also been identified (Gentsch et al., 2005; Santos
and Hoshino 2005; Bányai et al., 2012). Unusual and novel antigen
combinations have continued to emerge, some of them spreading
globally, such as G12P[8] (Matthijnssens et al., 2010), while some
strains have become important regionally or locally, such as G8P[6]
in parts of Africa and G12P[6] in parts of Asia (Cunliffe et al., 2010;
Ansari et al., 2013). Genetic interaction by reassortment among
co-circulating RVs contributes significantly to the great diversity of
G/P combinations (Iturriza-Gómara et al., 2001). Also, RVs are
ubiquitous in the animal kingdom, and interspecies transmission
and exchange of genetic material between the animal and human
strains is not rare, resulting in the emergence of novel RV strains,
some with epidemiological significance (Iturriza-Gómara et al.,
2004). The distribution of RV G/P combinations shows geographi-
cal and temporal fluctuations. Not only can the dominance of a
certain genotype change dramatically from year to year and from
country to country, but the incidence of RV genotypes in different
regions within the same country can differ during the same year
(Santos and Hoshino 2005; Ogilvie et al., 2011; Bányai et al., 2012).
In response to the substantial burden of RV disease among
children worldwide, RV vaccines have been developed as the most
effective preventive strategy. Two live-attenuated oral RV vaccines,
RotaTeq (Merck, Whitehouse Station, NJ, USA), a pentavalent (G1, G2,
G3, G4, P[8]) bovine–human reassortant vaccine, and Rotarix (GSK
Biologicals, Rixensart, Belgium), a monovalent (G1P[8]) human
strain vaccine, are currently recommended by the World Health
Organization (WHO) for introduction into routine immunization
programs worldwide (WER, 2009). Recently, two vaccines have been
added to the WHO list of prequalified vaccines: Rotavac (Bharat
Biotech International Ltd, Hyderabad, India), which contains a G9P
[11] human strain, and Rotasil (Serum Institute of India Ltd, Pune,Figure 1. Schematic representation of the geographical locations of the centers included 
census data (available at: https://www.dzs.hr/Hrv/censuses/census2011/results/censustIndia), a pentavalent (G1, G2, G3, G4, G9) bovine–human reassortant
vaccine (WHO, 2019). In Croatia, RV vaccines are not included as part
of the national immunization program and are only recommended
for children at higher risk (Hrvatski zavod za javno zdravstvo, 2017).
Before the introduction of an RV vaccine into a national immuniza-
tion program, it is important to obtain local epidemiological data on
the burden of RV disease, including the age distribution, seasonal
trends, and assessment of the circulating genotypes, in order to
create effective strategies to control the disease (Vesikari et al., 2008;
Matthijnssens et al., 2009).
In Croatia, data on the molecular epidemiology of the RV strains
responsible for acute gastroenteritis are limited. One study in 2007
described the genotype distribution of RVs in Central Croatia
(Zagreb metropolitan area) (Tcheremenskaia et al., 2007), but no
studies have included other regions of the country.
The aim of this study was to assess the prevalence of RV
genotypes in three different regions of Croatia (North, Central, and
South) in order to determine possible differences in geographical
distribution of RV genotypes and monitor the possible emergence
of novel RV strains in the selected regions. The data can be used to
direct policy decisions with regard to the introduction of RV
vaccine into the national immunization program.
Materials and methods
This prospective observational study was conducted during two
consecutive RV seasons, from July 2012 to July 2014, at three
hospitals representing three geographical regions of Croatia
(Figure 1): County Hospital Cakovec (situated in the northernmost
Croatian county), University Hospital for Infectious Diseases “Dr
Fran Mihaljevic”, Zagreb (city of Zagreb and Zagreb County –
Central Croatia), and University Hospital of Split (city of Split and
Split County – South Croatia). The study was approved by the ethics
committees of all three institutions and informed consent was
obtained from the patients’ caregivers before inclusion.in the study. Data on the catchment population 5 years of age are based on the 2011
absxls.htm, accessed September 15, 2018).
Table 2
Adjusted prevalence of PCR-confirmed rotavirus infections by site, age group, and
sex; differences are expressed as (adjusted) prevalence ratios (PR).
Prevalence (%) (95% CI) PR (95% CI) p-Value
Site
Zagreba 69.9 (66.4–73.5) 1.00 (reference) –
Splitb 77.3 (71.7–83.3) 1.11 (1.01–1.22) 0.039
Cakovecc 70.3 (64.1–77.1) 0.99 (0.90–1.10) 0.909
Age
12 months 75.6 (71.4–80.2) 1.00 (reference) –
>12 months 69.3 (65.3–73.4) 0.92 (0.84–0.99) 0.036
Sex
Female 74.2 (70.1–78.6) 1.00 (reference) –
Male 70.6 (66.9–74.5) 0.95 (0.88–1.02) 0.194
PCR, polymerase chain reaction; CI, confidence interval. The probability of a PCR-
confirmed infection was analyzed in a modified Poisson regression model with
robust error variance (models ln[risk] instead of ln[odds]).
a Central Croatia.
b South Croatia.
c North Croatia.
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All children aged 5 years with a diagnosis of acute
gastroenteritis, hospitalized or treated through the emergency
departments during the observation period were included in the
study. Acute gastroenteritis was defined as diarrhea (3 looser-
than-normal stools per day), with or without vomiting (1 episode
of forceful emptying of partially digested stomach contents 1
hour after feeding per day). Children with community-acquired
and hospital infections (patients hospitalized for other reasons
who developed acute gastroenteritis at >48 h after admission, or
patients who developed the disease within 72 h after hospital
discharge) were included. Children living in children’s homes and
those with chronic diarrhea, inflammatory bowel diseases, or
immune deficiencies were not included. Epidemiological and
demographic data (age, sex, geographical location, date of onset of
disease, date of sample collection) were collected and entered into
a database for linkage to the genotyping data.
One stool sample per patient was obtained and tested for RV
and the presence of adenoviral antigen using a single commercial
immunochromatographic assay, Rota-AdenoGnost test (BioGnost,
Hannover, Germany). RV-positive samples were stored at 20 C at
the local microbiology laboratories until shipment for molecular
typing at the Department of Clinical Microbiology, University
Hospital for Infectious Diseases, Zagreb, Croatia. Viral RNA was
extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions. A reverse
transcriptase PCR (RT-PCR) was conducted using the Qiagen
OneStep RT-PCR Kit (Qiagen, Hilden, Germany) with primers VP7-F
and VP7-R (Gómara et al., 2001) and VP4-F and VP4-R (Gentsch
et al., 1992), using a Veriti thermal cycler (Applied Biosystems,
Waltham, MA, USA). PCR typing was performed according to the
protocol of the European Rotavirus Detection and Typing Methods
(available at the EuroRotaNet website http://www.eurorota.net).
Samples that were non-typeable by PCR were submitted for DNA
sequencing using primers VP7-F, VP7-R, VP4-F, and VP4-R. The PCR
amplicons were purified using the QIAquick PCR Purification Kit
(Qiagen, Hilden, Germany). Sequencing was performed at
Macrogen Europe (Amsterdam, The Netherlands). Genotypes were
assigned using the RotaC v1.1 genotyping tool (http://rotac.
regatools.be).
Data analysis
Patient characteristics and observed crude prevalence rates
were summarized by site (region), age, and sex. The intended
stratification by age (12 months, 12–36 months, and >36 to 60
months) was changed to 12 and >12 months, since only 9.7% of
those for whom PCR was done and only 8.7% of those with PCR-
confirmed RV infection were older than 36 months. Prevalence
rates by site or age or sex adjusted for the other two factors wereTable 1
Subject characteristics; data are count (%) or median (range).
All By site (region) 
Zagreba Splitb Ca
ICT (+) and PCR done 1169 748 216 20
Age (months) 14.4 (0.03–60) 17.5 (0.13–60) 4.40 (0.03–58) 13
Age 0–12 months 417 (35.7) 209 (27.9) 155 (71.8) 53
Age >12 months 752 (64.3) 539 (72.1) 61 (28.2) 15
Male 653 (55.9) 403 (53.9) 142 (65.7) 10
Confirmed by PCR 822 (70.4) 512 (68.4) 169 (78.2) 14
ICT (+), immunochromatographically positive; PCR, polymerase chain reaction.
a Central Croatia.
b South Croatia.
c North Croatia.obtained from generalized linear models (by inverse link function).
Differences of interest were expressed as the relative difference
(adjusted prevalence ratios (PR), by modified Poisson regression
with robust error variance (models risk instead of odds) (Zou,
2004)), or as an absolute difference between adjusted prevalence
rates (by the method of variance estimates recovery (Newcombe,
2016)). SAS 9.4 for Windows was used for the analysis (SAS
Institute Inc., Cary, NC, USA).
Results
A total of 1545 children with an immunochromatographically
positive RV infectionwere enrolled. The centers contributed patients
in proportion with their catchment population (Figure 1). Due to
technical reasons, genotyping was not performed in 376 (24.3%)
cases (Figure 1). RV infection was confirmed by RT-PCR in 822/1169
(70.4%) processed samples (Figure 1). This proportion was higher in
Split (South Croatia) than at the other two sites (Figure 1, Table 1). It
wasalsohigher inchildren 12 monthsofage compared tothose>12
months of age (Table 1); however, children included in Split were
considerably younger than children included at the two other
centers (71.8% were 12 months of age vs. approximately 25% in the
other centers) (Table 1). Adjusted differences between centers and
between age groups were minor (Table 2).
In the 822 children with PCR-verified infection, G1 was by far the
predominant G-type, followed by G2 (three-fold lower prevalence),
while G3, G9, and G4 were sporadic (3%) (Figure 2). Only three
cases of ‘uncommon’ G-types (G6, G8) were observed (Figure 2). Of
the P-types, P[8] by far prevailed, followed by P[4] (three-fold less)
and one case of P[6] (‘uncommon’ type) (Figure 2). A number of
different G/P combinations were observed (Table 3). Overall, G1P[8]By age (months) By sex
kovecc 12 >12 Male Female
5 417 752 653 516
.2 (0.30–56) – – 13.4 (0.03–60) 15.2 (0.26–58)
 (25.8) – – 254 (38.9) 163 (31.6)
2 (74.2) – – 399 (61.1) 353 (68.4)
8 (52.7) 254 (60.9) 399 (53.1) – –
1 (68.8) 315 (75.5) 507 (67.4) 452 (69.2) 370 (71.7)
Figure 2. Overall prevalence of individual G and P types in 822 children with PCR-confirmed rotavirus gastroenteritis.
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genotypes (Table 3). Other genotypes were identified in <5% of the
samples, and G9P[8] accounted for 2.3% of the samples (Table 3).
Mixed infections with different P- or G-types were identified in
1.62% of cases. Strains that were non-typeable for the G- or P-type
accounted for 1.62 % of the samples (Table 3). The prevalence of the
two most common genotypes (G1P[8], G2P[4]) appeared different
across regions (Table 3), with slight differences also between age
groups and by sex (Table 3). The age and sex-adjusted prevalenceTable 3
Characteristics and identified rotavirus genotypes in children with PCR-confirmed infe
All By site (region) 
Zagreba Splitb Cak
Number 822 512 169 141 
Age (months) 13.5 (0.03–60) 17.6 (0.13–60) 4.00 (0.03–54) 13.2
Age 0–12 months 315 (38.3) 143 (27.9) 131 (77.5) 41 (
Age >12 months 507 (61.7) 369 (72.1) 38 (22.5) 100
Male 452 (55.0) 270 (52.7) 112 (66.3) 70 (
G1P[8] 509 (61.9) 293 (57.2) 108 (63.9) 108
G2P[4] 160 (19.5) 129 (25.2) 27 (16.0) 4 (2
G1P[4] 32 (3.9) 13 (2.5) 3 (1.8) 16 (
G3P[8] 24 (2.9) 6 (1.2) 17 (10.1) 1 (0
G2P[8] 22 (2.7) 22 (4.3) 0 0 
G9P[8] 19 (2.3) 14 (2.7) 5 (2.9) 0 
G4P[8] 18 (2.2) 13 (2.5) 4 (2.4) 1 (0
GNT P[8] 8 (1.0) 1 (0.2) 1 (0.6) 6 (4
G9P[4] 5 (0.6) 5 (1.0) 0 0 
G4P[4] 4 (0.5) 4 (0.8) 0 0 
G1P[4]+P[8] 4 (0.5) 1 (0.2) 0 3 (2
G1P[NT] 3 (0.4) 2 (0.4) 0 1 (0
G1+G2P[4]+P[8] 3 (0.4) 3 (0.6) 0 0 
G1+G2P[4] 1 (0.12) 1 (0.2) 0 0 
G1+G3P[4]+P[8] 1 (0.12) 0 1 (0.6) 0 
G1+G3P[8] 1 (0.12) 0 1 (0.6) 0 
G1+G9P[8] 1 (0.12) 0 1 (0.6) 0 
G2P[NT] 1 (0.12) 1 (0.2) 0 0 
G2P[4]+P[8] 1 (0.12) 1 (0.2) 0 0 
G4P[6] 1 (0.12) 1 (0.2) 0 0 
G6P[4] 1 (0.12) 1 (0.2) 0 0 
G6P[4]+P[8] 1 (0.12) 0 1 (0.6) 0 
G8P[8] 1 (0.12) 1 (0.2) 0 0 
GNT P[4] 1 (0.12) 0 0 1 (0
PCR, polymerase chain reaction; NT, non-typeable.
a Central Croatia.
b South Croatia.
c North Croatia.(Table 4) of G1P[8] was approximately 20% higher, and the
prevalence of G2P[4] was approximately 20% lower in the North
compared to the Central and South Croatia regions. Observed
prevalence rates of the less common genotypes also varied
somewhat by region, age, and sex (Table 3). Age and sex-adjusted
prevalence rates (Table 4) indicated the following: (1) a moderate
prevalence of G1P[4] (around 10%) in the North compared to <2.2%
in other regions; (2) a notable prevalence of P[8] (non-typeable G) in
the North (around 4.4%) compared to sporadic (<0.5%) in otherction; data are count (%) or median (range).
By age (months) By sex
ovecc 12 >12 Male Female
315 507 452 370
 (0.30–56) – – 13.2 (0.03–60) 14.8 (0.26–57)
29.1) – – 185 (40.9) 130 (35.1)
 (70.9) – – 267 (59.1) 240 (64.9)
49.7) 185 (58.7) 267 (52.7) – –
 (76.6) 213 (67.6) 296 (64.7) 291 (64.4) 218 (58.9)
.8) 49 (15.6) 111 (21.9) 78 (17.3) 82 (22.2)
11.3) 8 (2.5) 24 (4.7) 18 (4.0) 14 (3.8)
.7) 14 (4.4) 10 (2.0) 14 (3.1) 10 (2.7)
5 (1.6) 17 (3.3) 12 (2.6) 10 (2.7)
6 (1.9) 13 (2.6) 10 (2.2) 9 (2.4)
.7) 5 (1.6) 13 (2.6) 12 (2.6) 6 (1.6)
.3) 4 (1.3) 4 (0.8) 3 (0.7) 5 (1.3)
2 (0.6) 3 (0.6) 4 (0.9) 1 (0.3)
1 (0.3) 3 (0.6) 1 (0.2) 3 (0.8)
.1) 0 4 (0.8) 1 (0.2) 3 (0.8)
.7) 2 (0.6) 1 (0.2) 2 (0.4) 1 (0.3)
0 3 (0.6) 0 3 (0.8)
1 (0.3) 0 0 1 (0.3)
1 (0.3) 0 1 (0.2) 0
1 (0.3) 0 1 (0.2) 0
1 (0.3) 0 0 1 (0.3)
1 (0.3) 0 1 (0.2) 0
0 1 (0.2) 0 1 (0.3)
0 1 (0.2) 1 (0.2) 0
0 1 (0.2) 0 1 (0.3)
0 1 (0.2) 1 (0.2) 0
0 1 (0.2) 0 1 (0.3)
.7) 1 (0.3) 0 0 1 (0.3)
Table 4
Age and sex-adjusted prevalence (%) (95% CI) of individual genotypes by site (region). Only genotypes with an observed prevalence of 1.0% at any site are shown. Values in
bold are those that numerically stand out at a particular site vs. Zagreb (Central Croatia) as the ‘reference’ site. The column ‘Difference’ contains the absolute prevalence
difference: value in bold – ‘reference’.
Genotype Zagreba Splitb Cakovecc Difference (95% CI)
G1P[8] 59.5 (54.8–64.1) 60.3 (52.2–67.9) 78.4 (70.9–84.4) 18.9 (10.1, 26.5)
G2P[4] 23.6 (19.7–27.9) 17.9 (12.5–25.1) 2.6 (0.9–6.7) 21.0 (25.6, 15.3)
G1P[4] 2.2 (1.2–4.1) 1.9 (0.6–5.9) 10.2 (6.0–16.9) 8.0 (3.4, 14.8)
G3P[8] 1.1 (0.5–2.5) 11.0 (6.5–17.8) 0.7 (0.1–4.6) 9.9 (5.2, 16.7)
G2P[8] 4.0 (2.5–6.4) 0 0 –
G9P[8] 2.4 (1.2–4.4) 3.4 (1.4–8.1) 0 –
G4P[8] 2.0 (1.0–4.0) 2.4 (0.9–6.6) 0.6 (0.1–4.1) –
GNT P[8] 0.2 (0.0–1.5) 0.5 (0.0–3.8) 4.4 (1.9–9.9) 4.2 (1.4, 9.7)
G9P[4] 0.8 (0.3–2.6) 0 0 –
G1P[4]+P[8] 0.2 (0.0–1.3) 0 1.8 (0.5–6.3) –
CI, confidence interval; NT, non-typeable. A separate generalized linear model was fitted to probability of individual genotypes.
a Central Croatia.
b South Croatia.
c North Croatia.
M. Vrdoljak et al. / International Journal of Infectious Diseases 89 (2019) 3–9 7regions; (3) a moderate prevalence of G3P[8] (around 11%) in the
South compared to sporadic (1.0%) in the other regions.
Discussion
This is the first Croatian national study to describe the
molecular epidemiology of RV strains among children under 5
years of age in three different regions of Croatia: North, Central,
and South. One previous study conducted in 2005–2006 in a
wider area of Central-Eastern Europe (Croatia, Czech Republic,
Slovenia, Albania, and Bulgaria) included RV samples only from
the Zagreb metropolitan area, i.e. Central Croatia (Tcheremen-
skaia et al., 2007).
RV gastroenteritis associated with severe dehydration mainly
affects children under 5 years of age. However, in developed
countries, RV infections are more common in children 9–15 months
of age (Zeller et al., 2010), while in the low-income countries, most of
the RV infections are detected in children <1 year of age (Gasparinho
et al., 2017; Boni-Cisse et al., 2018). The age distribution of patients
overall and in Central and North Croatia showed a pattern similar to
that in developed countries (median age 14.4,17.5, and 13.2 months,
respectively). Patients in South Croatia tended to be much younger,
with a median age of 4.4 months.
Five RV strains (‘common’ genotypes G1P[8], G2P[4], G3P[8], G4P
[8], and G9P[8]) were found to be responsible for the majority of
severe RV infections worldwide in the pre-vaccine era (Gentsch et al.,
2005; Santos and Hoshino, 2005; Bányai et al., 2012) and have
remained predominant in the post-vaccine licensure period (Dóró
et al., 2014). We detected numerous G- and P-types of RV circulating
in the Croatianpopulation: seven G-types (G1, G2,G3, G4, G6, G8, G9)
and three P-types (P[8], P[4], P[6]) occurring in diverse genotype
combinations. However, the majority of cases in all three regions
were caused by genotype G1P[8] (57.2% in Central, 63.9% in South,
and 76.6% in North, respectively). The prevalence of the globally
‘common’ G/P combinations was 88.8% overall and between 81% and
95% across the regions. This pattern of high prevalence of ‘common’
RV strains is typical of the developed countries of North America,
Europe, and Australia (Santos and Hoshino, 2005) and is in contrast
with previous findings in Croatia, where the G1P[8] genotype was
detected in less than 22% of the samples and the total prevalence of
‘common’ G/P combinations was less than 60% (Tcheremenskaia
et al., 2007). This suggests that the distribution and prevalence of
particular RV genotypes changes over time and that one genotype
can be replaced by another, as described in several studies (Ogilvie
et al., 2011; Bányai et al., 2012; Dóró et al., 2014).
Interestingly, the G9 strain, which has emerged as the one of the
globally most common G-types, including in Europe (Cubitt et al.,2000; Martella et al., 2003; Santos and Hoshino, 2005; Van Damme
et al., 2007; De Rougemont et al., 2009, 2011; Bányai et al., 2012),
was found in only 25 samples (3.02%) in the present study: as G9P
[8] in 2.3%, G9P[4] in 0.6%, and as a part of a mixed genotype in
0.12% of the samples. A similar unusually low rate of G9 has been
reported previously in Croatia, where G9 accounted for only 2.2% of
the G-types (Tcheremenskaia et al., 2007). Of note, G9 was not
found in North Croatia in the present study.
Besides the ‘common’ human RV strains, ‘uncommon’ G/P
combinations were also found that might have originated from
reassortment between common human strains or animal and
human strains (Iturriza-Gómara et al., 2001; Gentsch et al., 2005).
Genotypes that presented reassortments among the common
human RV genotypes were G1P[4] (3.9%), G2P[8] (2.7%), G9P[4]
(0.6%), and G4P[4] (0.5%). Of note, the G1P[4] genotype was the third
most frequent genotype overall and the second most common in
North Croatia, where it accounted for 11.3% of all genotypes. Possible
human–animal hybrid RV strains were detected sporadically (total
0.36%): G4P[6], G6P[4], and G8P[8]. Such a high prevalence of G1P[4]
genotype has rarely been reported (Abdel-Haq et al., 2003).
Furthermore, this unusually high percentage of ‘uncommon’
genotypes (8.06%), especially human–human reassortants (7.7%),
isnot typical forEuropeancountries, where it has been reported with
a prevalence of around 1% (Iturriza-Gómara et al., 2011). Similar
findings have already been described in Croatia and suggest probable
horizontal transmission of some reassortant strains, since their
prevalence remained high in the previous study (Tcheremenskaia
et al., 2007) and in the current study.
Another interesting finding is the appearance of the G6 type,
which has not been described previously in Croatia (Tcheremen-
skaia et al., 2007). The G6 type is one of the most common G types
found in cattle (Martella et al., 2010), but has also been identified in
children with acute gastroenteritis worldwide, mostly sporadically
(Rahman et al., 2003; De Grazia et al., 2011; Iturriza-Gómara et al.,
2011; Afrad et al., 2013). In some countries, such as Hungary, the G6
type was detected with a higher prevalence of 1% and became one
of the emerging genotypes (Bányai et al., 2004). In the present
study, it was found in only two samples: in a combination with P[4]
and as a part of a mixed genotype G6P[4]+P[8]. Interestingly, the
samples were from two different geographical regions – one from
the South and one from the North Croatia region. Since G6 strains
are very common in cattle, they were probably transmitted to
humans directly from an animal reservoir (De Grazia et al., 2011) or
arose by interspecies transmission accompanied by reassortment
(Bányai et al., 2003). It will be important to monitor the
transmission and prevalence of the G6 type in Croatia, since it is
not incorporated in the available RV vaccines and it is not known
8 M. Vrdoljak et al. / International Journal of Infectious Diseases 89 (2019) 3–9whether vaccine strains would ensure sufficient heterotypic
protection against this type.
Unlike the previous report of a high prevalence of mixed
genotypes in Croatia (Tcheremenskaia et al., 2007), in this study
they were observed in less than 2% of the samples, similar to the
findings in developed countries (Iturriza-Gómara et al., 2011).
Mixed infections are significant because they may contribute to the
generation of unusual antigen combinations by gene reassortment
in vivo (Bányai et al., 2004), and their prevalence is often higher in
developing countries where greater variation of different genotype
combinations is also usually detected (Gentsch et al., 2005).
This study revealed significant differences in distribution of the
most common genotypes among different regions. It has already
been reported that the prevalence of individual RV genotypes
shows continental and subcontinental variations, but it can also
differ between regions in the same country (Santos and Hoshino,
2005; Ogilvie et al., 2011; Bányai et al., 2012). It is interesting that
greater differences were found between North and Central Croatia,
which are geographically closely related, than between Central and
South Croatia, which are not in a direct geographical contact. It is
assumed that many factors affect RV diversity in a certain region:
the intensity of the horizontal transmission between humans
(which in Croatia is also driven by extensive migration from South
to Central Croatia), reassortment of human strains, zoonotic
transmission, and probably some other factors.
This study has several limitations. A considerable proportion of
immunochromatographically positive RV samples (16.0–30.9%,
depending on the center) could not be amplified by RT-PCR. Since
immunochromatographic tests for the detection of RV are highly
specific (97–100%) (Kaplon et al., 2015), such a high percentage of RV
infections not confirmed by PCR cannot be explained only by false-
positive results. Probable explanations include technical issues,
inadequate storage and transportation of the samples (destructionof
viral RNA), or too low viral load that was not sufficient for further
analysis. Another limitation is that not all of the immunochromato-
graphically positive samples were sent for further molecularanalysis
(1.0–28.4%), which could have affected the final results. Finally, the
study was conducted in the major hospital centers in Croatia, which
may not be representative of the whole population.
In conclusion, this study provides pre-vaccination data impor-
tant for decisions regarding immunization strategies in Croatia,
where RV vaccine has still not been introduced into the national
immunization program. The high prevalence of ‘common’ RV
strains circulating in Croatia may advocate for RV vaccine
introduction. However, a possible change in the predominant RV
strains and emergence of the new reassortants in circulation
highlight the need for continuous surveillance.
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